股票简称：海思科 股票代码：002653 海思科医药集团股份有限公司 海思科医药集团股份有限公司（以下简称"公司"、"海思科"）是一家在深 圳证券交易所上市的公司，股票简称为"海思科"，股票代码为 002653.SZ。为 满足公司业务发展的资金需求，增强公司的资本实力和盈利能力，根据《中华人 民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以下简 称"《公司法》"）、《上市公司证券发行注册管理办法》（以下简称"《注册管理办 法》"）、《上市公司证券发行注册管理办法》第九条、第十条、第十一条、第十三 条、第四十条、第五十七条、第六十条有关规定的适用意见——证券期货法律适 用意见第 18 号（以下简称"《证券期货法律适用意见第 18 号》"）等有关法律、 行政法规、部门规章和《公司章程》的规定，公司编制了 2025 年度向特定对象 发行 A 股股票募集资金使用的可行性分析报告。 本论证报告如无特别说明，相关用语具有与《海思科医药集团股份有限公司 2025 年度向特定对象发行 A 股股票预案》中相同的含义。 一、本次募集资金使用计划 本次向特定对象发行股票募集资金总额不超过 124,525.6 ...

证券代码：002653 证券简称：海思科 公告编号：2025-107 | | | 集资金总额上限及募集资金投向安 | | --- | --- | --- | | | | 排 | | 第一节 本次向特定对象 | 一、发行人基本情况 | 更新公司法定代表人等信息 | | | 二、本次向特定对象发行股 | 更新公司研发投入和新药临床进展 | | | 票的背景和目的 | | | 发行股票概要 | 四、本次向特定对象发行股 | 更新本次向特定对象发行股票募集 | | | 票方案概要 | 资金总额上限及募集资金投向安排 | | | 八、本次发行取得批准的情 | 更新本次向特定对象发行已履行决 | | | 况及尚需呈报批准的程序 策程序 | | | | 一、本次募集资金使用计划 | 更新本次向特定对象发行股票募集 | | 第二节 董事会关于本次 | | 资金总额上限及募集资金投向安排 | | 募集资金使用的可行性 | 二、本次募集资金投资项目 | 更新公司业务进展及研发团队情 | | 分析 | 的必要性和可行性分析 | 况；更新补充流动资金项目的投资 | | | 总额 | | | 第三节 董事会关于本次 | 六、本次股票发 ...

证券代码：002653 证券简称：海思科 公告编号：2025-105 海思科医药集团股份有限公司 第五届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 海思科医药集团股份有限公司（以下简称"公司"）第五届董事 会第三十次会议于 2025 年 9 月 23 日以通讯表决方式召开，会议通知 已于 2025 年 9 月 19 日以书面、电子邮件、电话等方式发出。本次会 议应出席的董事 5 人，实际出席并参与表决的董事 5 人，会议由董事 长王俊民先生主持。本次会议的通知、召开以及参与表决董事人数均 符合有关法律、法规、规则及《公司章程》的有关规定。 二、会议表决情况 经参会董事审议，依法表决，本次会议审议通过了以下议案： （一）审议通过《关于调整公司 2025 年度向特定对象发行 A 股股 票方案的议案》 议案内容： 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司证券发行注册管理办法》及《证券期货法律适用意见第 18 号》的 规定，募集资金用于补充流动资金和偿还债务的比例不得超过募集资 金总额的百分之三 ...

Group 1 - The core announcement is about the approval of the drug Remimazolam injection for use in children, expanding its application in anesthesia [1][2] - The drug, developed by the company, is a new class of intravenous anesthetic that was approved for domestic use in December 2020 and has shown significant clinical value, especially in pediatric patients [2][3] - The drug has demonstrated good tolerance and lower pain response at the injection site, making it a safer and more comfortable option for patients requiring anesthesia [2] Group 2 - The company has submitted a New Drug Application (NDA) to the FDA for the product, which was accepted for review in July 2025 [3] - The drug has already received registration certificates for multiple indications, including sedation and anesthesia during non-intubation surgeries and in intensive care settings [2] - The company emphasizes the cardiovascular safety of the drug, supported by comprehensive clinical trials [2]

Group 1 - The company announced that a significant shareholder, Ms. Fan Xiulian, has pledged part of her shares, with no major asset restructuring or performance compensation obligations involved [1] - As of the announcement date, the total pledged shares by the shareholder and their concerted parties were detailed, although specific figures were not disclosed [1] Group 2 - The company received approval from the National Medical Products Administration for its drug, Remifentanil Injection, to expand its use to pediatric populations for anesthesia induction and maintenance [3][4] - Remifentanil Injection is a novel intravenous anesthetic developed by the company, which was approved for domestic use in December 2020 and has shown significant clinical value, particularly in reducing pain response at injection sites and demonstrating good tolerance in pediatric patients [5] - The company submitted a New Drug Application (NDA) to the FDA for this product in July 2025, which is currently under review [6]

Core Viewpoint - Recently, the company announced that its subsidiary, Shenyang Hisun Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplementary application of the drug,环泊酚注射液 (Ropivacaine Injection) [1] Company Summary - Hisun Pharmaceutical's subsidiary has successfully obtained the approval for Ropivacaine Injection, indicating a positive development in its product portfolio [1]

Core Viewpoint - Company Haisco (002653.SZ) has received approval from the National Medical Products Administration for its new drug, Ropivacaine Injection, which is a novel intravenous anesthetic with independent intellectual property rights [1] Group 1: Product Development - The product, Ropivacaine Injection (also known as "Sishuning®"), is classified as a Class 1 intravenous anesthetic [1] - It was approved for domestic market launch in December 2020 [1] - The drug has obtained registration certificates for multiple indications, including sedation and anesthesia during non-tracheal intubation surgeries, induction and maintenance of general anesthesia, and sedation during intensive care [1]

Core Viewpoint - Company subsidiary Shenyang Haishike Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the use of Ropivacaine injection in pediatric and adolescent general anesthesia induction and maintenance, marking a significant advancement in pediatric anesthesia options [1] Group 1: Product Approval - The approval includes a revised safety information in the product's instructions [1] - Ropivacaine is a new Class I intravenous anesthetic developed by the company, which has already been approved for multiple indications in China [1] Group 2: Clinical Value - The product offers a more comfortable and safer option for pediatric patients, demonstrating excellent clinical application value [1] Group 3: Regulatory Progress - The company has submitted a New Drug Application (NDA) for the product to the FDA, which is currently under review [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for a supplemental application regarding the use of its drug, Ropivacaine Injection, specifically for pediatric and adolescent anesthesia [1] Group 1 - The subsidiary, Shenyang Haishike Pharmaceutical Co., Ltd., is the entity that received the approval [1] - The approved supplemental application includes indications for the use of Ropivacaine Injection in the induction and maintenance of general anesthesia in children and adolescents [1] - The approval also involves revisions to the safety information in the drug's instructions [1]

Core Viewpoint - Company received approval from the National Medical Products Administration for a supplemental application regarding the use of Ropivacaine injection in children and adolescents for anesthesia induction and maintenance, along with revised safety information in the product instructions [1] Group 1 - Company subsidiary Shenyang Haishike Pharmaceutical Co., Ltd. has been granted a supplemental approval for Ropivacaine injection [1] - The approval includes specific usage guidelines for children and adolescents undergoing general anesthesia [1] - The product instructions have been updated to reflect new safety information [1]